# 3BNC117 and 10-1074 in ART-treated Individuals

> **NCT03526848** · PHASE1 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 26 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** 3BNC117
- **DRUG:** 10-1074
- **OTHER:** Analytical treatment interruption

## Key facts

- **NCT ID:** NCT03526848
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-05
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-02-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526848, "3BNC117 and 10-1074 in ART-treated Individuals". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03526848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*